Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide is a synthetic small molecule with the chemical formula C10H8N4O2S2. It is primarily characterized as a benzimidazole derivative containing both thiazole and sulfonamide functional groups. The compound has been identified in chemical databases and research literature but does not have any approved medical indications or clinical trial data as of now. Its main known biological activity is inhibition of carbonic anhydrase 2 (CA II), an enzyme involved in the regulation of acid-base balance and fluid secretion in various tissues. There are no marketed products or known developers/manufacturers for this compound[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide.